Rahamat Unissa

Dr. Rahamat Unissa


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Asian Journal of Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
RURahamat Unissa
Rahamat Unissa
BMBayyaram Monica
Bayyaram Monica
SKSowmya Konakanchi
Sowmya Konakanchi
RDRahul Darak
Rahul Darak
SKSandagalla Lipi Keerthana
Sandagalla Lipi Keerthana
SKSaranya Arun Kumar
Saranya Arun Kumar
Thalassemia is a group of inherited diseases of the blood that affect a person's ability to produce hemoglobin, resulting in anemia. Around 100, 000 cases of thalassemia'sare found every year in the new born babies. Chances of occurrence of these cases are more among people of Italian, Greek, Middle Eastern, Southern Asian and African Ancestry. Thereare two main types of thalassemia are called "alpha" and "beta, " depending on which part of an oxygen-carrying protein in the red blood cells is lacking. Both types of thalassemia are inherited in the same manner. The disease is passed to children by parents who carry the mutated thalassemia gene. A child who inherits one mutated gene is a carrier, which is sometimes called "thalassemia trait." Most carriers lead completely normal, healthy lives. Diagnosis is usually done by hematologic tests, hemoglobin electrophoresis, and DNA analysis. Individuals with severe thalassemia require blood transfusion, drug therapy i.e. deferoxamine, deferasirox, deferiprone, and bone marrow transplant. Bone Marrow Transplant (BMT) is still remains the only definitive cure available for patients with Thalassemia. The present paper discuss about the various types of Thalassemia's, their etiology, pathophysiology, clinical features, complication, prevention and treatment.

19 October 2022 in Life
Verified
Journal Article
Open access
PDF file
RURahamat Unissa
Rahamat Unissa
SMSivakumar Sivagurunathan Moni
Sivakumar Sivagurunathan Moni
ALAmr Abu Lila
Amr Abu Lila
MAMarwa H. Abdallah
Marwa H. Abdallah
Amr Salah AbouziedAmr Salah Abouzied
Amr Salah Abouzied
MTManal Mohamed Elhassan Taha
Manal Mohamed Elhassan Taha
The objective of this study was to characterize the bioactive ingredients and antiulcer effects of Lactuca sativa leaves. Several bioactive chemicals were found in the cold methanolic extract of Lactuca sativa leaves after gas chromatography-mass spectrometry (GC-MS) research: 9,12-octadecadienoic acid (Z,Z)-, cyclononasiloxane, octadecamethyl-, n-hexadecanoic acid, Hexadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl, octadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester, 9-octadecenamide, (Z)-, hexadecanoic acid, stigmasterol, benzothiazole, ethyl iso-allocholate, and octacosane. Distinct fingerprint regions in GCMS indicated the existence of bioactive compounds. The leaf powder of Lactuca sativa (LPL) demonstrated substantial antiulcer properties at 400 mg/kg, which was almost equivalent to the standard drug at 20 mg/kg. The cytokine network was efficiently regulated by reducing the production of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α. The levels of caspase-3 and caspase-9 were also considerably lowered at p < 0.05 significant level.

26 June 2022 in Entropy
Verified
Journal Article
Open access
PDF file
THTalib Hussain
Talib Hussain
AHAlaa Hamed Habib
Alaa Hamed Habib
MRMisbahuddin M Rafeeq
Misbahuddin M Rafeeq
AAAhmed Alafnan
Ahmed Alafnan
EKEl-Sayed Khafagy
El-Sayed Khafagy
Syed Mohd Danish RizviSyed Mohd Danish Rizvi
Syed Mohd Danish Rizvi
The association of COVID-19 with neurological complications is a well-known fact, and researchers are endeavoring to investigate the mechanistic perspectives behind it. SARS-CoV-2 can bind to Toll-like receptor 4 (TLR-4) that would eventually lead to α-synuclein aggregation in neurons and stimulation of neurodegeneration pathways. Olive leaves have been reported as a promising phytotherapy or co-therapy against COVID-19, and oleuropein is one of the major active components of olive leaves. In the current study, oleuropein was investigated against SARS-CoV-2 target (main protease 3CLpro), TLR-4 and Prolyl Oligopeptidases (POP), to explore oleuropein potency against the neurological complications associated with COVID-19. Docking experiments, docking validation, interaction analysis, and molecular dynamic simulation analysis were performed to provide insight into the binding pattern of oleuropein with the three target proteins. Interaction analysis revealed strong bonding between oleuropein and the active site amino acid residues of the target proteins. Results were further compared with positive control lopinavir (3CLpro), resatorvid (TLR-4), and berberine (POP). Moreover, molecular dynamic simulation was performed using YASARA structure tool, and AMBER14 force field was applied to examine an 100 ns trajectory run. For each target protein-oleuropein complex, RMSD, RoG, and total potential energy were estimated, and 400 snapshots were obtained after each 250 ps. Docking analyses showed binding energy as −7.8, −8.3, and −8.5 kcal/mol for oleuropein-3CLpro, oleuropein-TLR4, and oleuropein-POP interactions, respectively. Importantly, target protein-oleuropein complexes were stable during the 100 ns simulation run. However, an experimental in vitro study of the binding of oleuropein to the purified targets would be necessary to confirm the present study outcomes.

13 October 2021 in Processes
Verified
Journal Article
Open access
PDF file
Syed Mohd Danish RizviSyed Mohd Danish Rizvi
Syed Mohd Danish Rizvi
Talib HussainTalib Hussain
Talib Hussain
THTalib Hussain
Talib Hussain
DDDr. Sheshagiri Ravindra Dixit
Dr. Sheshagiri Ravindra Dixit
SMSubhankar P. Mandal
Subhankar P. Mandal
RURahamat Unissa
Rahamat Unissa
Background: The outbreak of the coronavirus (SARS-CoV-2) has drastically affected the human population and caused enormous economic deprivation. It belongs to the β-coronavirus family and causes various problems such as acute respiratory distress syndrome and has resulted in a global pandemic. Though various medications have been under trial for combating COVID-19, specific medicine for treating COVID-19 is unavailable. Thus, the current situation urgently requires effective treatment modalities. Nigella sativa, a natural herb with reported antiviral activity and various pharmacological properties, has been selected in the present study to identify a therapeutic possibility for treating COVID-19. Methods: The present work aimed to virtually screen the bioactive compounds of N. sativa based on the physicochemical properties and docking approach against two SARS-CoV-2 enzymes responsible for crucial functions: 3CLpro (Main protease) and NSP15 (Nonstructural protein 15 or exonuclease). However, simulation trajectory analyses for 100 ns were accomplished by using the YASARA STRUCTURE tool based on the AMBER14 force field with 400 snapshots every 250 ps. RMSD and RMSF plots were successfully obtained for each target. Results: The results of molecular docking have shown higher binding energy of dithymoquinone (DTQ), a compound of N. sativa against 3CLpro and Nsp15, i.e., −8.56 kcal/mol and −8.31 kcal/mol, respectively. Further, the dynamic simulation has shown good stability of DTQ against both the targeted enzymes. In addition, physicochemical evaluation and toxicity assessment also revealed that DTQ obeyed the Lipinski rule and did not have any toxic side effects. Importantly, DTQ was much better in every aspect among the 13 N. sativa compounds and 2 control compounds tested. Conclusions: The results predicted that DTQ is a potent therapeutic molecule that could dual-target both 3CLpro and NSP15 for anti-COVID therapy.

28 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RURahamat Unissa
Rahamat Unissa
SMSivakumar Sivagurunathan Moni
Sivakumar Sivagurunathan Moni
MNMuhammad Nawaz
Muhammad Nawaz
MBMohammed Khaled Bin Break
Mohammed Khaled Bin Break
NKNasrin Eldirdiri Khalifa
Nasrin Eldirdiri Khalifa
EAEntsar Mohammed Alhaidan
Entsar Mohammed Alhaidan
Amikacin sulfate-loaded dextran sulfate sodium nanoparticles were formulated, lyophilized (LADNP), and then analyzed. The LADNP had a −20.9 ± 8.35 mV zeta potential, PDI of 0.256, and % PDI of 67.7. The zeta average nano size of LADNP was 317.9 z. d.nm, while the dimension of an individual particle was 259.3 ± 73.52 nm, and nanoparticle conductivity in colloidal solution was 2.36 mS/cm. LADNP has distinct endothermic peaks at temperatures at 165.77 °C, according to differential scanning calorimetry (DSC). The thermogravimetric analysis (TGA) showed the weight loss of LADNP, which was observed as 95% at 210.78 °C. XRD investigation on LADNP exhibited distinct peaks at 2θ as 9.6°, 10.4°, 11.4°, 18.9°, 20.3°, 24.4°, 28.2°, 33.2°, 38.9°, and 40.4° confirming crystalline structure. The amikacin release kinetics from LADNP revealed zero order kinetics with a linear release showed zero order kinetics with 37% of drug release in 7 h and had an R2 value of 0.99. The antibacterial effect of LADNP showed broad-spectrum activity against tested human pathogenic bacteria. The preset study demonstrated that LADNP is a promising antibacterial agent.

1 January 2018 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
PDF file
RURahamat Unissa
Rahamat Unissa
DVDevaragattu Bhargav Varma
Devaragattu Bhargav Varma
NKNaga Santhosh Kesana
Naga Santhosh Kesana
CSChekalta Srinivas
Chekalta Srinivas
BRBaddanapally Shalem Raj
Baddanapally Shalem Raj
Hepatocellular carcinoma (HCC) is one of the most common types of malignancies that carries poor prognosis worldwide. Accumulating evidences suggest the beneficial effects of amino acid-depleting enzymes in lowering the risk of various cancers. Herein, we investigated the in vitro antioxidant (DPPH) and anticancer effects of Lglutaminase produced by Idiomarina sediminum; H1695 against Hep-G2 cell lines by MTT assay. Collectively, these findings indicate a crucial role of L-glutaminase in liver cancer.